St. George, Utah

Sermorelin & Growth
Hormone Peptides

A more physiologic alternative to HGH — sermorelin and related peptides tell your pituitary to release your own growth hormone, within natural feedback limits. Medically supervised by Janessa Kraupp-Sampson, MSN, FNP-BC.

A More Physiologic Approach

The most important thing to understand about sermorelin and related peptides: they don't inject growth hormone. They signal your own pituitary to release growth hormone — within the body's natural feedback limits. Your body still controls how much GH is released, when, and how it's metabolized. The pituitary can't be pushed past its physiologic ceiling.

This matters because direct HGH injection bypasses regulation. High-dose HGH does drive aggressive results, but with significant side effects — water retention, joint pain, insulin resistance, and increased risk of certain conditions at sustained high doses. Sermorelin-class peptides work within the system rather than around it: gentler curve, fewer side effects, lower cost, no risk of pushing GH supraphysiologically.

Sermorelin vs CJC-1295 vs Ipamorelin vs Tesamorelin

Sermorelin

The original GHRH analog. Short-acting (matches natural pulses). The starting point for most patients. Good safety record, modest cost.

CJC-1295 (with DAC)

A modified GHRH that's longer-acting — extends GH release across a wider time window. Often combined with ipamorelin for synergistic effect.

Ipamorelin

Triggers GH release through a different receptor (the ghrelin receptor) without affecting cortisol or appetite as some older peptides did. Often paired with CJC-1295 for combined dual-pathway stimulation.

Tesamorelin

A longer-acting GHRH analog — FDA-approved for HIV-related visceral fat. Used off-label for visceral fat reduction in patients with that specific concern. More expensive than the others.

Lab-Driven, Not Anecdote-Driven

Hormone-related peptide therapy without baseline labs is a red flag. Aera always runs baseline labs before starting — IGF-1 (the downstream marker of GH activity), CMP, lipid panel, A1c, and thyroid function. We repeat IGF-1 at 8–12 weeks to verify the peptide is producing the expected response and at 6-month intervals throughout therapy.

Patients with elevated baseline IGF-1, untreated thyroid disease, certain cancers, or pregnancy aren't appropriate candidates. Janessa screens for contraindications during the consultation and won't start therapy without proper workup. If your provider isn't doing labs, find a different provider.

Provider

Janessa Kraupp-Sampson, MSN, FNP-BC

Board-certified Family Nurse Practitioner with prescriptive authority in Utah — meaning she can directly prescribe and supervise hormone-related peptide therapy, order labs, and manage protocols. Master of Science in Nursing. Clinical foundation in primary care and dermatology.

All peptide therapies →

Frequently Asked Questions

Sermorelin is a synthetic growth hormone-releasing hormone (GHRH) — it's not growth hormone itself, but it tells your pituitary gland to release your own growth hormone (GH). This is fundamentally different from injecting synthetic HGH, which bypasses your body's regulatory feedback. Sermorelin restores a more physiologic pattern of GH release, with most of the effect happening during natural sleep cycles. Sermorelin was previously FDA-approved as Geref but is no longer commercially manufactured; it's now available through 503A compounding pharmacies under valid prescription.

HGH (human growth hormone) is direct administration of synthetic GH — high doses, supraphysiologic levels, and bypassing the body's negative feedback regulation. It's effective but has a more significant side-effect profile (water retention, joint pain, insulin resistance, increased risk of certain conditions at high doses). Sermorelin tells your pituitary to release its own GH within physiologic limits — gentler effects, fewer side effects, lower cost, and can't push GH beyond what your body's regulation allows. HGH is FDA-approved for specific conditions (adult GH deficiency); sermorelin is compounded and used for optimization.

Reported benefits include: improved sleep quality and depth (most consistent and earliest-reported effect), increased energy and endurance, faster recovery from exercise, gradual improvements in body composition (modest fat loss, lean muscle support), improved skin elasticity over time, and improved mood and cognitive function in some patients. Effects are typically gradual — most patients notice sleep and energy changes at 2–4 weeks, with body composition changes emerging over 3–6 months.

These are all growth hormone-releasing peptides with slightly different mechanisms: CJC-1295 is a longer-acting GHRH analog that extends sermorelin's effect window; ipamorelin is a ghrelin mimetic that triggers GH release through a different receptor (often combined with CJC-1295 for synergistic effect); tesamorelin is a longer-acting GHRH analog FDA-approved for HIV-related lipodystrophy and used off-label for visceral fat reduction. Janessa selects based on your specific goals, age, lab work, and budget.

At Aera Medical Aesthetics, sermorelin protocols typically run $400–$700 per month including the peptide, injection supplies, and follow-up. CJC-1295 + ipamorelin combinations are typically $500–$800/month. Tesamorelin is more expensive at $700–$1,200/month given its current pricing. Cost varies with current pharmacy pricing — Janessa quotes specific pricing at consultation.

Yes. Before starting any growth hormone-releasing peptide, we run baseline labs including IGF-1 (the downstream marker of GH activity), complete metabolic panel, lipid panel, hemoglobin A1c, and thyroid function. We repeat IGF-1 at 8–12 weeks to monitor response and at 6-month intervals during ongoing therapy. Patients with elevated IGF-1, certain cancers, or severe metabolic disease may not be appropriate candidates.

Sermorelin and ipamorelin are generally well-tolerated. Most-common side effects: injection-site redness or tenderness, mild headache (typically resolves within first week), occasional flushing, transient water retention at higher doses. Rare but possible: insulin sensitivity changes (we monitor with A1c). Patients with active cancer, untreated thyroid disease, or pregnancy should not use these peptides.

Subcutaneous injection (similar to insulin pens), typically administered before bed to align with the body's natural overnight GH release. Most protocols are 5 nights per week with 2 nights off, in 3-month cycles followed by an evaluation. Patients are taught proper at-home injection technique at the start of therapy.

Sleep improvements: typically 1–2 weeks. Energy increases: 2–4 weeks. Recovery improvements: 4–6 weeks. Body composition changes: 3–6 months. Skin elasticity improvements: 6+ months. The earliest and most consistent effect is improved sleep depth — patients often report deeper, more restorative sleep before any other change is visible.

Ready to Get Started?

Schedule your complimentary consultation with Janessa Kraupp-Sampson, MSN, FNP-BC at Aera Medical Aesthetics in St. George, Utah.

393 E Riverside Dr, Ste 103, St. George, UT 84790